Literature DB >> 29955149

Saccharomyces cerevisiae-like 1 (SEC14L1) is a prognostic factor in breast cancer associated with lymphovascular invasion.

Sultan N Sonbul1,2, Mohammed A Aleskandarany1,3, Sasagu Kurozumi1, Chitra Joseph1, Michael S Toss1, Maria Diez-Rodriguez1, Christopher C Nolan1, Abhik Mukherjee1, Stewart Martin1, Carlos Caldas4, Ian O Ellis1, Andrew R Green1, Emad A Rakha5,6.   

Abstract

Lymphovascular invasion is strongly related to breast cancer metastasis. However, the underlying mechanisms of lymphovascular invasion and its driver molecules in breast cancer remain to be defined. In this study, we explore differential expression of genes in large molecularly characterized and clinically annotated datasets of invasive breast cancer patients (n = 8056) coupled with histological review and strict definition for lymphovascular invasion status. The METABRIC series was used to identify genes associated with lymphovascular invasion, as defined using hematoxylin and eosin staining supplemented by immunohistochemistry, at the genomic/transcriptomic levels. Saccharomyces cerevisiae-like 1 (SEC14L1) was identified as one of the most significant genes associated with lymphovascular invasion. The prognostic significance of SEC14L1 gene copy number and mRNA expression was further investigated in the METABRIC series and externally validated using the Breast Cancer Gene-Expression Miner v4.0. Protein expression of SEC14L1 was also assessed using immunohistochemistry in series of early stage breast cancer using tissue microarrays. SEC14L1 gene copy number gain was significantly associated with high histological grade and poor outcome. SEC14L1 mRNA expression showed positive association with higher grade, lymph node metastasis, and poor outcome. SEC14L1 protein overexpression was significantly associated with lymphovascular invasion (p < 0.0001), higher grade (p = 0.011), HER2 positivity (p = 0.036), and shorter survival (p = 0.00075). Our findings specify SEC14L1 as an independent prognostic factor in breast cancer. Its association, at both transcriptome and protein expression levels, with lymphovascular invasion and outcome could imply an important role in tumor progression. A further mechanistic insight into its molecular roles including potential therapeutic utility is warranted.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29955149     DOI: 10.1038/s41379-018-0092-9

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  7 in total

1.  Upregulation of Cyclin B2 (CCNB2) in breast cancer contributes to the development of lymphovascular invasion.

Authors:  Abrar I Aljohani; Michael S Toss; Khloud A El-Sharawy; Sameer Mirza; Graham R Ball; Andrew R Green; Emad A Rakha
Journal:  Am J Cancer Res       Date:  2022-02-15       Impact factor: 6.166

Review 2.  Lipid metabolism-related proteins of relevant evolutionary and lymphoid interest (PRELI) domain containing family proteins in cancer.

Authors:  Yue Zhu; Renrui Zou; Huanhuan Sha; Ya Lu; Yuan Zhang; Jianzhong Wu; Jifeng Feng; Dongfeng Wang
Journal:  Am J Transl Res       Date:  2020-10-15       Impact factor: 4.060

3.  Myxovirus resistance 1 (MX1) is an independent predictor of poor outcome in invasive breast cancer.

Authors:  Abrar I Aljohani; Chitra Joseph; Sasagu Kurozumi; Omar J Mohammed; Islam M Miligy; Andrew R Green; Emad A Rakha
Journal:  Breast Cancer Res Treat       Date:  2020-04-29       Impact factor: 4.872

4.  The prognostic significance of wild-type isocitrate dehydrogenase 2 (IDH2) in breast cancer.

Authors:  Abrar I Aljohani; Michael S Toss; Sasagu Kurozumi; Chitra Joseph; Mohammed A Aleskandarany; Islam M Miligy; Rokaya El Ansari; Nigel P Mongan; Ian O Ellis; Andrew R Green; Emad A Rakha
Journal:  Breast Cancer Res Treat       Date:  2019-10-10       Impact factor: 4.624

5.  Vitamins D2 and D3 Have Overlapping But Different Effects on the Human Immune System Revealed Through Analysis of the Blood Transcriptome.

Authors:  Louise R Durrant; Giselda Bucca; Andrew Hesketh; Carla Möller-Levet; Laura Tripkovic; Huihai Wu; Kathryn H Hart; John C Mathers; Ruan M Elliott; Susan A Lanham-New; Colin P Smith
Journal:  Front Immunol       Date:  2022-02-24       Impact factor: 7.561

6.  Radiomics in Gastric Cancer: First Clinical Investigation to Predict Lymph Vascular Invasion and Survival Outcome Using 18F-FDG PET/CT Images.

Authors:  Liping Yang; Wenjie Chu; Mengyue Li; Panpan Xu; Menglu Wang; Mengye Peng; Kezheng Wang; Lingbo Zhang
Journal:  Front Oncol       Date:  2022-03-30       Impact factor: 6.244

7.  Mitochondrial fission regulator 2 (MTFR2) promotes growth, migration, invasion and tumour progression in breast cancer cells.

Authors:  Guanming Lu; Yuanhui Lai; Tiantian Wang; Weihao Lin; Jinlan Lu; Yanfei Ma; Yongcheng Chen; Haiqing Ma; Ruilei Liu; Jie Li
Journal:  Aging (Albany NY)       Date:  2019-11-18       Impact factor: 5.682

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.